MEVROMETOSTAT (PF-06821497) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE: THE PHASE 3, RANDOMIZED MEVPRO-1 STUDY

被引：0
|
作者：
Neeraj, Agarwal [1 ]
Michael, T. Schweizer [1 ]
Elena, Castro [1 ]
Arun, A. Azad [1 ]
Daniel, J. George [1 ]
Jayeta, Chakrabarti [1 ]
Sujata, Narayanan [1 ]
Yiyun, Tang [1 ]
Karim, Fizazi [1 ]
机构：
[1] Univ Utah, Huntsman Canc Inst NCI CCC, Salt Lake City, UT USA
来源：
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2025年 / 43卷 / 03期
关键词：
D O I：
10.1016/j.urolonc.2024.12.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    de Boer, Carla
    Todd, Mary
    Yu, Margaret K.
    Scher, Howard I.
    CANCER RESEARCH, 2014, 74 (19)
  • [22] Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
    Takashi Kawahara
    Yusuke Saigusa
    Shuko Yoneyama
    Masashi Kato
    Ippei Kojima
    Hiroshi Yamada
    Osamu Kamihira
    Kenichi Tabata
    Hideyasu Tsumura
    Masatsugu Iwamura
    Kazuhide Makiyama
    Hiroji Uemura
    Yasuhide Miyoshi
    BMC Cancer, 23
  • [23] Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
    Kawahara, Takashi
    Saigusa, Yusuke
    Yoneyama, Shuko
    Kato, Masashi
    Kojima, Ippei
    Yamada, Hiroshi
    Kamihira, Osamu
    Tabata, Kenichi
    Tsumura, Hideyasu
    Iwamura, Masatsugu
    Makiyama, Kazuhide
    Uemura, Hiroji
    Miyoshi, Yasuhide
    BMC CANCER, 2023, 23 (01)
  • [24] Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 804 - 804
  • [25] Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 800 - 801
  • [26] Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis
    Brasso, Klaus
    Thomsen, Frederik B.
    Schrader, Andres J.
    Schmid, Sebastian C.
    Lorente, David
    Retz, Margitta
    Merseburger, Axel S.
    von Klot, Christoph A.
    Boegemann, Martin
    de Bono, Johann
    EUROPEAN UROLOGY, 2015, 68 (02) : 317 - 324
  • [27] The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
    Cem, Onal
    Sedef, Ali Murat
    Kose, Fatih
    Oymak, Ezgi
    Guler, Ozan Cem
    Sumbul, Ahmet Taner
    Aksoy, Sercan
    Yildrim, Berna Akkus
    Besen, Ali Ayberk
    Mullaoglu, Sadik
    Mertsoylu, Huseyin
    Ozyigit, Gokhan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [28] Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy- naive Metastatic Castration-resistant Prostate Cancer Patients
    Azad, Arun A.
    Eigl, Bernhard J.
    Murray, R. Nevin
    Kollmannsberger, Christian
    Chi, Kim N.
    EUROPEAN UROLOGY, 2015, 67 (01) : 23 - 29
  • [29] Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
    Di Lorenzo, Giuseppe
    Sonpavde, Guru
    Pond, Gregory
    Lucarelli, Giuseppe
    Rossetti, Sabrina
    Facchini, Gaetano
    Scagliarini, Sarah
    Carteni, Giacomo
    Federico, Piera
    Daniele, Bruno
    Morelli, Franco
    Bellelli, Teresa
    Ferro, Matteo
    De Placido, Sabino
    Buonerba, Carlo
    EUROPEAN UROLOGY FOCUS, 2018, 4 (06): : 874 - 879
  • [30] Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate
    Fiala, Ondrej
    Hosek, Petr
    Korunkova, Hana
    Hora, Milan
    Kolar, Jiri
    Sorejs, Ondrej
    Topolcan, Ondrej
    Filipovsky, Jan
    Liska, Vaclav
    Santoni, Matteo
    Buti, Sebastiano
    Finek, Jindrich
    CANCER MEDICINE, 2024, 13 (01):
12345